Photocure’s Cevira shows positive interim results for treatment of precancerous lesions of the cervix
Six-month interim data presented at international conference addressing prevention of cervical cancer
Photocure presented positive interim data at the six-month follow up stage of its phase I/II clinical feasibility study with Cevira™ at the EUROGIN 2008 international conference. Cevira™ is Photocure’s photodynamic therapy (PDT) in development as a new treatment of precancerous lesions of the cervix (CIN) induced by persistent human papilloma virus (HPV) infection.
The six-month clinical data from 35 patients in Norway showed that 73% patients with moderate grade lesions (CIN2) were treated successfully as determined by complete regression of lesions confirmed through a normal biopsy (histology) and cell sampling (cytology). 38% of patients with more severe (CIN3) lesions also responded positively to Cevira treatment.
A complete response of the lesions correlated with the eradication of HPV in 87% of the responding patients. Importantly, the treatment was well tolerated with cervical tissue preserved and completely normalized after PDT treatment.
Cevira PDT is being studied in women with cervical precancerous lesions who are eligible for surgery to remove the affected tissues, the current standard of care. The ongoing study involves 92 patients at two clinical centers in Germany and Norway, all of whom will be followed for 12 months after treatment.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models

Triple-threat cancer-fighting polymer capsules for guided drug delivery created
New prostate cancer treatment may be riskier
Genzyme and Bayer HealthCare Enter New Strategic Agreement - Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis

Billion-euro takeover: Roche joins the fight against obesity
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Immune system reveals new ways to treat brain disease and pain
Genomatix partners with Research Instruments Pte Ltd for Singapore, Malaysia and Thailand markets

The 2013 Nobel Prize in Physiology or Medicine: Machinery regulating vesicle traffic
